The Gateway Pundit reported in July that the FDA approved Emergent BioSolution’s new anthrax vaccine for adults 18-65.
The FDA approved Emergent Biosolution’s Cyfendus for use following any confirmed or suspected exposure to anthrax, but it was also noted it must be administered with antibacterial drugs.
Now Emergent BioSolutions has announced that the U.S. Biomedical Advanced Research and Development Authority (BARDA) has “exercised an option valued on an existing deal to procure additional doses of its recently approved anthrax vaccine Cyfendus (AV7909).”
The additional doses bought by BARDA will cost an additional $75 million.
In case you are unfamiliar with the office of BARDA, it is an office under the U.S. Department of Health and Human Services (HHS) office that is in charge of the procurement and research of medical countermeasures, mostly against bioterrorism and emerging pandemics.
$EBS
After Cyfendus’ full approval, Emergent clinches $75M anthrax vaccine supply pact in US https://t.co/z3fo5KfVuS
— Bio/Tech Stock Focus (@MarcJacksonLA) November 28, 2023
The Gateway Pundit reported in October that public safety, health, and emergency management agencies across the state of Ohio conducted a three-day anthrax attack simulation.
WATCH:
Ohio isn’t the only one concerned with a possible attack. Federal agencies have claimed if a bioterrorist attack were to occur, it’s likely anthrax would be used in the attack.
Per the CDC’s website, “If a bioterrorist attack were to happen, Bacillus anthracis, the bacteria that causes anthrax, would be one of the biological agents most likely to be used.”
READ:
The post U.S. Governmnent Inks $75 Million Contract for Recently Approved Anthrax Vaccines appeared first on The Gateway Pundit.